At last someone recognises that the real test of the interferons should relate to disability progression not relapses:
Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.
Rio J, Nos C, Tintore M, Tellez N, Galan I, Pelayo R, Comabella M, Montalban X.
Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
OBJECTIVE: Many patients with multiple sclerosis (MS) are currently receiving treatment with interferon (IFN)-beta. Early identification of nonresponder patients is crucial ...